Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): primary analysis results from the randomized, open-label, phase 3 study Candor (NCT03158688)

Authors
Publication date
1 January 2019
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens

    redirect
    oaioai:lib.uoa.gr:uoadl:2952834
    Last time updated on 10/02/2023

    Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens

    redirect
    oaioai:lib.uoa.gr:uoadl:2954966
    Last time updated on 10/02/2023